全文获取类型
收费全文 | 60937篇 |
免费 | 5067篇 |
国内免费 | 495篇 |
专业分类
耳鼻咽喉 | 941篇 |
儿科学 | 1328篇 |
妇产科学 | 1286篇 |
基础医学 | 9384篇 |
口腔科学 | 1099篇 |
临床医学 | 5660篇 |
内科学 | 12252篇 |
皮肤病学 | 1783篇 |
神经病学 | 5070篇 |
特种医学 | 3267篇 |
外科学 | 7720篇 |
综合类 | 684篇 |
现状与发展 | 1篇 |
一般理论 | 28篇 |
预防医学 | 3691篇 |
眼科学 | 1707篇 |
药学 | 5036篇 |
中国医学 | 510篇 |
肿瘤学 | 5052篇 |
出版年
2023年 | 297篇 |
2022年 | 556篇 |
2021年 | 1631篇 |
2020年 | 929篇 |
2019年 | 1392篇 |
2018年 | 1608篇 |
2017年 | 1192篇 |
2016年 | 1762篇 |
2015年 | 2296篇 |
2014年 | 2717篇 |
2013年 | 3184篇 |
2012年 | 4602篇 |
2011年 | 4537篇 |
2010年 | 2792篇 |
2009年 | 2367篇 |
2008年 | 3383篇 |
2007年 | 3396篇 |
2006年 | 3054篇 |
2005年 | 2859篇 |
2004年 | 2468篇 |
2003年 | 2180篇 |
2002年 | 1943篇 |
2001年 | 1284篇 |
2000年 | 1212篇 |
1999年 | 1016篇 |
1998年 | 454篇 |
1997年 | 418篇 |
1996年 | 351篇 |
1995年 | 329篇 |
1994年 | 293篇 |
1993年 | 298篇 |
1992年 | 705篇 |
1991年 | 720篇 |
1990年 | 627篇 |
1989年 | 681篇 |
1988年 | 650篇 |
1987年 | 642篇 |
1986年 | 553篇 |
1985年 | 555篇 |
1984年 | 435篇 |
1983年 | 363篇 |
1982年 | 267篇 |
1981年 | 249篇 |
1980年 | 221篇 |
1979年 | 318篇 |
1978年 | 272篇 |
1977年 | 204篇 |
1974年 | 206篇 |
1973年 | 227篇 |
1972年 | 179篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Moderate sedatives have been increasingly used to improve patient comfort during flexible bronchoscopy (FB). However, routine use of moderate sedation during FB is controversial because its efficacy and safety are not well established.This study aims to evaluate the efficacy and safety of moderate sedation during FB.A search was made of Medline, EMBASE, and the Cochrane Library to May 2014.Randomized controlled trials (RCTs) and quasi-RCTs were included.The main analysis was designed to examine the efficacy of moderate sedation during FB in sedation than no-sedation.The willingness to repeat FB was significantly more in sedation than no-sedation (odds ratio [OR] 2.30; 95% confidence interval [CI] 1.11–4.73; P = 0.02; I2 = 22.5). The duration of FB was shorter in sedation group than no-sedation group (standardized mean difference [SMD] −0.21; 95% CI −0.38 to −0.03; P = 0.02; I2 = 78.3%). Event of hypoxia was not significantly different between sedation and no-sedation groups (OR 0.86; 95% CI 0.42–1.73; P = 0.67; I2 = 0%). The SpO2 during procedure was not different between sedation and no-sedation groups (SMD −0.14; 95% CI −0.37 to 0.08; P = 0.21; I2 = 49.9%). However, in subgroup analysis without supplemental oxygen, the SpO2 was significantly lower in sedation than no-sedation group (SMD −0.45; 95% CI −0.78 to −0.11; P = 0.01; I2 = 0.0%).According to this meta-analysis, moderate sedation in FB would be useful in patients who will require repeated bronchoscopies as well as safe in respiratory depression. To our knowledge, although the various sedative drugs are already used in the real field, this analysis was the first attempt to quantify objective results. We anticipate more definite and studies designed to elucidate standardized outcomes for moderate sedation in FB. 相似文献
3.
Hyun Jong Choi Jong Ho Moon Yun Nah Lee Hyun Su Kim Ji Su Ha Tae Hoon Lee Sang‐Woo Cha Young Deok Cho Sang‐Heum Park 《Digestive endoscopy》2015,27(7):772-775
Direct peroral cholangioscopy (POC) using an ultra‐slim upper endoscope is one modality of POC for intraductal endoscopic evaluation and treatment of the bile duct. Choledochoduodenostomy (CDS) is one modality of biliary bypass surgery that provides a new route to the bile duct. We carried out direct POC using an ultra‐slim upper endoscope without the use of accessories in 10 patients (four sump syndromes, three bile duct strictures and three intrahepatic duct stones) previously undergoing surgical CDS. Direct POC was successful in all patients. The use of an intraductal balloon catheter was required in one patient for advancement of the endoscope into the bile duct. Distal bile ducts with sump syndromes were cleared using baskets and water irrigation under direct POC. Cholangiocarcinoma was diagnosed in one patient with hilar bile duct stricture after cholangioscopic evaluation and a targeting forceps biopsy under direct POC. Intrahepatic duct stones were successfully extracted after intraductal fragmentation under direct POC. Oozing bleeding occurred during intraductal lithotripsy but stopped spontaneously. Direct POC using an ultra‐slim upper endoscope without the assistance of accessories can easily be carried out in patients undergoing CDS. 相似文献
4.
5.
6.
7.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
8.
Richard Kim Elaine Tan Emily Wang Amit Mahipal Dung-Tsa Chen Biwei Cao Fadzai Masawi Cindy Machado James Yu Dae Won Kim 《The oncologist》2020,25(12):e1893-e1899
Lessons Learned
- The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
- Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
- The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
9.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention 下载免费PDF全文
10.